Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat ...

Hemophilia is a serious condition that can limit the ability to avoid episodes of bleeding. Treatment includes regular infusions of proteins to replace what the body doesn’t produce naturally.

Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

People with hemophilia A bleed and bruise easily, and their blood takes a long time to form clots. Hemophilia A is a rare, serious condition that has no cure, but is treatable. Hemophilia A is ...

Opens in a new tab or window Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets ...

Weak demand for Pfizer’s hemophilia gene therapy Beqvez has led the pharmaceutical company to “cease further development and commercialization” of the one-time treatment, a Pfizer spokesperson ...

Hemophilia B is an X-linked recessive hemorrhagic disorder caused by a deficiency or abnormality of clotting factor IX. Human factor IX is a vitamin-K-dependent multidomain glycoprotein composed ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...